← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › ALKYLATING AGENTS › Nitrogen mustard analogues
trofosfamide
L01AA07
Forms & Strengths
- Capsules: 50mg, 100mg, 200mg, 500mg
- Vials for injection: 1g, 2.5g, 5g
- Oral solutions: 50mg/mL
Adult Dosing
- Typical dose: 50-200mg orally or 100-500mg intravenously per day
- Dose adjustment for renal impairment: reduce dose by 50% if creatinine clearance < 10mL/min
- Dose escalation: increase by 50mg daily every 5-7 days as needed
Pediatric Dosing
- Not established for children under 12 years
- Children 12-18 years: dose as for adults, with close monitoring
Indications
- Palliative treatment of various cancers, including ovarian, breast, and bronchial carcinomas
- Second-line treatment for soft tissue sarcomas
- Treatment of malignant effusions
Mechanism of Action
- Alkylating agent, cross-linking DNA strands and inhibiting DNA replication and transcription
- Induces apoptosis and stops cell division in cancer cells
Contraindications
- Severe bone marrow depression
- Severe renal or hepatic impairment
- Previous hypersensitivity to trofosfamide or other oxazaphosphorine compounds
Adverse Reactions
- Bone marrow suppression
- Nausea and vomiting
- Diarrhea and abdominal pain
- Alopecia, fatigue, and anorexia
Drug Interactions
- Myelosuppressive effects increased by other chemotherapeutic agents or radiation therapy
- Reduced efficacy when combined with anticonvulsants or other enzyme-inducing medications
- Interaction with allopurinol may increase risk of xanthine nephropathy
Curated Content: Needs Vetting Before Put to Clinical Use